Novo Nordisk and its Chinese partner have reported up to 19.7% weight loss in patients who took their triple agonist for 24 weeks, illuminating a potential path forward for the Danish drugmaker as it ...

UBT251 "triple G" obesity drug posts 19.7% weight loss vs 2.0% placebo in a mid-stage China trial after 24 weeks.

COPENHAGEN, Feb 24 (Reuters) - Novo Nordisk and United Laboratories International said on Tuesday a Chinese mid-stage trial of their jointly developed "triple G" UBT251 obesity drug candidate resulted ...

(Reuters) -Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G" weight-loss drug candidate in a deal worth up to $2 billion.

Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight loss in a Phase III trial. In the TRIUMPH-4 trial, retatrutide, a first-in-class glucose-dependent insulinotropic polypeptide (GIP), ...